Curriculum Vitae Fabio Guolo. Via F. Marabotto 120/2, 16151, Genova, Italia

Transcript

1 INFORMAZIONI PERSONALI Fabio Guolo Via F. Marabotto 120/2, 16151, Genova, Italia Data di nascita 12/03/1986 Nazionalità Italiana ESPERIENZA PROFESSIONALE 05/07/ /07/ /11/2017 a tutt oggi Medico Specializzando presso la scuola di specializzazione in Ematologia dell Università degli studi di Genova. V.le Benedetto XV 6, Genova. Direttore: Prof. Marco Gobbi. Dottorato di Ricerca presso l Università degli Studi di Genova, corso di Medicina Traslazionale in Ematologia ed Oncologia, curriculum Ematologia Traslazionale, con attività di Ricerca Clinica presso l U.O. Clinica Ematologica dell Ospedale Policlinico San Martino di Genova. V.le Benedetto XV 6, Genova. Direttore: Prof. Marco Gobbi. Largo R. Benzi 10, Genova, Direttore Prof. Marco Gobbi. 01/12/2018 a tutt oggi Delegato Regionale per la Regione Liguria della Società Italiana di Ematologia Via Marconi, Bologna. Presidente: Prof. P. Corradini. ISTRUZIONE E FORMAZIONE (05/07/ /07/2017) (6/03/2012) (03/10/2005/ - 28/07/2011) Specializzazione in Ematologia con votazione 50/50 lode Abilitazione all esercizio della professione di Medico-Chirurgo con votazione finale 258,75/270 ed iscrizione all albo Professionale. Laurea Specialistica In Medicina e Chirurgia con votazione 109/110. Università degli Studi di Genova, Via Balbi 5, Genova. COMPETENZE PERSONALI Lingua madre Italiano Altre lingue COMPRENSIONE PARLATO PRODUZIONE SCRITTA Ascolto Lettura Interazione Produzione orale Inglese C1 C1 C1 C1 C1 Francese C1 C1 C1 B2 B2 PET DELF Livelli: A1/2 Livello base - B1/2 Livello intermedio - C1/2 Livello avanzato Quadro Comune Europeo di Riferimento delle Lingue Unione europea, Pagina 1 / 8

2 Competenze informatiche ECDL Buona capacità di utilizzo di ambiente Linux, Windows e MacOS Buona capacità di utilizzo di Microsoft Office/Open Office Buona capacità di utilizzo di programmi di analisi statistica (IBM SPSS e R) Patente di guida Patente A,B Unione europea, Pagina 2 / 8

3 Pubblicazioni Nucleophosmin gene-based monitoring in de novo cytogenetically normal acute myeloid leukemia with nucleophosmin gene mutations: comparison with cytofluorimetric analysis and study of Wilms tumor gene 1 expression. Leuk emia and Lymphoma Nov;53(11): De novo AML patients with favourable-intermediate karyotype may benefit from the addition of lowdose gemtuzumab ozogamicin (GO) to fludarabine, Ara-C and idarubicin (FLAI): a contribution to the reopened "GO question". Annals of Hematology ; 92(10): Integrating post induction WT1 quantification and flow-cytometry results improves minimal residual disease stratification in acute myeloid leukemia. Leuk Res ; 37(12): Management Of Early Stage Chronic Myeloid Leukemia: State-Of-The-Art Approach And Future Perspectives. Curr Cancer Drug Targets ; 13(7): Safety and efficacy of (90) yttrium-ibritumomab-tiuxetan for untreated follicular lymphoma patient. An Italian cooperative study. Br J Haemal 2014; 164(5):710-6 Bloodstream infections are an improbable cause of positive serum (1,3)-B-d-Glucan in Hematology patients. Clin Vaccine Immunol 2014;21(9): Liposomal daunorubicin, fludarabine, and cytarabine (FLAD) as bridge therapy to stem cell transplant in relapsed and refractory acute leukemia. Ann Hematol 2014; [Epub ahead of print] Combined assessment of WT1 and BAALC gene expression at diagnosis may improve leukemia-free survival prediction in patients with Myelodysplastic Syndromes. Leuk Res 2015; just accepted. Chronic graft versus host disease as a weapon for treating chronic myelomonocytic leukemia. Leuk Res Apr;43: High feasibility and antileukemic efficacy of fludarabine, cytarabine, and idarubicin (FLAI) induction followed by risk-oriented consolidation: A critical review of a 10-year, single-center experience in younger, non M3 AML patients. Am J Hematol Aug;91(8): Intesive fludarabine-high dose cytarabine-idarubicin combination as induction therapy with riskadapted consolidation may improve treatment efficacy in younger Acute Myeloid Leukemia (AML) patients: Rationales, evidences and future perspectives.. Biosci Trends Mar 22;11(1): doi: /bst Epub 2017 Jan 24. Good tolerability of high dose colistin-based therapy in patients with haematological malignancies. Infection Mar 28. doi: /s [Epub ahead of print] Combining flow cytometry and WT1 assessment improves the prognostic value of pre-transplant minimal residual disease in acute myeloid leukemia.haematologica May 11. pii: haematol doi: /haematol [Epub ahead of print] Impact of HLA Disparity in Haploidentical Bone Marrow Transplantation Followed by High-Dose Cyclophosphamide. Biol Blood Marrow Transplant Jan;24(1): doi: /j.bbmt Epub 2017 Oct 9. Depletion of SIRT6 enzymatic activity increases acute myeloid leukemia cells' vulnerability to DNAdamaging agents. Haematologica Jan;103(1): doi: /haematol Epub 2017 Oct 12. Prompt detection of L-asparaginase inactivation is crucial to optimize treatment efficacy also in aggressive lymphomas. Hematol Oncol Oct 20. doi: /hon [Epub ahead of print] No abstract available. A blastic plasmacytoid dendritic cell neoplasm-like phenotype identifies a subgroup of npm1-mutated acute myeloid leukemia patients with worse prognosis. Am J Hematol Feb;93(2):E33-E35. doi: /ajh Epub 2017 Nov 17. No abstract available. Early minimal residual disease assessment after AML induction with fludarabine, cytarabine and idarubicin (FLAI) provides the most useful prognostic information. Br J Haematol Just accepted. Performance of serum (1,3)-ß-D-glucan screening for the diagnosis of invasive aspergillosis in neutropenic patients with haematological malignancies. Mycoses Apr 25. doi: /myc [Epub ahead of print] Unione europea, Pagina 3 / 8

4 Rapidly ascending necrotizing myelopathy with widespread brain white matter involvement following intrathecal methotrexate and cytosine arabinoside treatment in an adult with T cell acute lymphoblastic leukemia. Neurol Sci May 4. doi: /s x. Congressi Presentazione al 54 ASH annual meeting and exposition tenutosi dal 8 al 11/12/2012 ad Atlanta (CA) del poster: Detection of an Unbalanced Ratio Between WT1 Isoforms in Acute Myeloid Leukemia and Its Correlation with Molecular Abnormalities e del poster Minimal Residual Disease After the First Cycle of Chemotherapy in Acute Myeloid Leukemia: A Comparative Study of WT1 RQ-PCR and 4- Color Flow Cytometry. Presentazione al 19 EHA congress tenutosi dal 12 al 15/06/2014 a Milano (I) del poster: combined assessment of WT1 and BAALC expression levels improbe risk stratification in Myelodisplastic syndromes e del poster Prognostic value of minimal residual disease before allogeneic marrow transplantation in acute myeloid leukemia by combined WT1 expression levels and flow cytometry assessment. Presentazione al 56 ASH annual meeting and exposition tenutosi a San Francisco (CA) dal 6 al 08/12/2014 dei poster: Fludarabine, Cytarabine and Idarubicine with or without Gemtuzumab ozogamicin is an effective and well tolerated regimen for younger AML patients: real life data from a single center register e Prognostic value of combined assessment of minimal residual disease before allotransplantation in acute myeloid leukemia by WT1 expression levels and flow cytometry. Presentazione al 20EHA congress tenutosi dal 11 al 14/06/2015 a Vienna (A) del poster: Fludarabinecontaining induction increases minimal residual disease clearance and improves survival in AML patients with concomitant NPM1 and FLT3-ITD mutations, del poster High cure rate of younger AML patients with Fludarabina, Cytarabine and Idarubicine induction and risk oriented consolidation: tenyears real life experience, del poster Azacytidine therapy in elderly previously untreated AML patients: comparison with conventional chemotherapy in a matched-paired analysis e del poster High prognostic value of pre transplant minimal residual disease assessment by combined WT1 expression and flow cytometry in acute myeloid leukemia patients (premiato con Travel Grant). Presentazione orale al congress o nazionale della Società Italiana di Ematologia del 2015, tenutosi a Firenze (I) del lavoro La valutazione dei livelli pre-trapianto di malattia minima residua traminte l analisi integrate dei livelli di espressione di WT1 e della citometria a flusso presenta un elevato valore prognostico nei pazienti affetti da leucemia acuta mieloide Presentazione al 57ASH annual meeting and exposition tenutosi dal 5 al 8/12/2015 a Orlando (Fl) del poster High prognostic value of pre transplant minimal residual disease assessment by combined WT1 expression and flow cytometry in acute myeloid leukemia patients (Premiato per Abstract Achievment award) e del poster High prognostic value of a 3-genes molecular score in non high risk acute promyelocytic leukemia patients treated with AIDA 2000 protocol: a retrospective study from regional register Presentazione al 21EHA congress tenutosi dal 11 al 14/06/2016 a Copenaghen (D) del poster: A blastic plasmacytoid dendritic cell neoplasm-like phenotype identifies a subgroup of NPM1-mutated AML patients with worse prognosis, del poster High prognostic value of a 3-genes molecular score in non high risk acute promyelocytic leukemia patients treated with AIDA 2000 protocol: a retrospective study from regional register, del poster MFC-MRD assessment may drive post induction consolidation in intermediate risk AML. Is it time for MRD-Driven decision making?, e del poster High prognostic value of pre transplant minimal residual disease assessment by combined WT1 expression and flow cytometry in acute myeloid leukemia patients (premiato con Travel Grant). Presentazione orale al 58ASH annual meeting and exposition, tenutosi dal 3 al 6/12/2016 a San Diego (CA) del lavoro Combining Flow Cytometry and Molecular Assessment Improves the Prognostic Value of Pre-Transplant Minimal Residual Disease in Acute Myeloid Leukemia" e dei posters : Minimal Residual Disease Assessment May Drive Post Remission Therapy in Acute Myeloid Leukemia. It's Time for MRD-Driven Therapy ; Finding the Best Therapy for Elderly Frail AML Patients: A Retrospective Comparison of 5-Azacytidine and Intensive Approach ; SIRT6 Inhibition As a Novel Approach for Treating Acute Myeloid Leukemia ; CD38 Deregulation As Strategy to Make Multiple Myeloma Cells More Sensitive to NAD+ Depleting Agents. Unione europea, Pagina 4 / 8

5 Presentazione al 22 EHA congress tenutosi a Madrid (E) dei posters Induction with tyrosine kinase inhibitors, consolidation with fludarabine, ara-c and daunoxome followed by allogeneic stem cell transplant is an effective and feasible strategy for Ph+ ALL patients, Optimization of minimal residual disease evaluation in acute myeloid leukemia to drive post remission therapy., MRD-driven choice of consolidation and modulation of induction and consolidation intensity resulted in a significantly improved outcome of younger AML patients in the last three years, Treatment of molecular relapse in acute myeloid leukemia with mutated NPM1 reduces toxicity of salvage treatment and improves disease clearance., Cytogenetic and molecular risk factors at diagnosis are overcome by WT1 and flow cytometry-based pre transplant minimal residual disease assessment in advanced acute myeloid leukemia patients., A comprehensive analysis of patient- and therapy-related factors affecting the toxicity of pegylated-asparaginase for the treatment of adult acute lymphoblastic leukemia., and Retrospective evaluation on efficacy and feasibility of R-CODOX-M/IVAC regimen in aggressive DLBCL. Comunicazione Orale al 46 Congresso della società Italiana di Ematologia, tenutosi a Roma (I) in Ottobre 2017 del lavoro: Minimal residual disease assessment in Acute Myeloid Leukemia with mutated NPM1: prospective evaluation and MRD directed therapy, partecipazione della stesura del lavoro presentato oralmente allo stesso congresso: The choice of cut off value at different time points is crucial to improve the prognostic role of minimal residual disease evaluation in acute myeloid leukemia. Presentazione del poster Comprehensive analysis of patient- and therapy-related factors affecting the toxicity of pegylated-asparaginase for the treatment of adult acute lymphoblastic leukemia Presentazione al 59th ASH annual meeting and exposition tenutosi in Dicembre 2017 ad Atlanta (GA): First Report of the Gimema LAL1811 Phase II Prospective Study of the Combination of Steroids with Ponatinib As Frontline Therapy of Elderly or Unfit Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia, Glutamine-Dependence Targeting By Asparaginase Significantly Increases Anti-Myeloma Activity of Proteasome Inhibitors, Comparison of the Efficacy and Feasibility of R-CODOX-M/IVAC-R Versus Conventional R-CHOP As First Line Regimen for High Risk Diffuse Large B-Cell Lymphoma, Pre-Transplant Minimal Residual Disease Evaluation Performed By Molecular WT1-Based or Multicolor Flow Cytometry Assessment Overcomes the Prognostic Value of Cytogenetic and Molecular Risk Factors at Diagnosis in Advanced Acute Myeloid Leukemia Patients, Patient and Therapy-Related Factors Affecting the Toxicity of Pegylated-Asparaginase for the Treatment of Adult Acute Lymphoblastic Leukemia. Conferenze Partecipazione in qualità di docente al congresso internazionale Management of invasive fungal infections in neutropenic patients: overview on prophylaxis and therapy tenutosi il 5/03/2013 a Genova (NH Marina). Partecipazione alla fase finale del concorso Under 40 in Hematology tenutosi a Torino il novembre 2013 con il progetto di ricerca: CGH/SNP Array and Next Generation Sequencing in newly diagnosed AML a possible role in risk stratification and prognostic evaluation. Partecipazione alla fase finale del concorso Under 40 in Hematology tenutosi a Roma il novembre 2014 con la presentazione: Total Lymphoid Irradiation with helical tomotherapy (tomo-tli) followed by High-Dose Melphalan and Autologous Hematopoietic Stem-Cell Transplantation (ahsct) for Relapsed and Refractory Hodgkin Lymphoma. Partecipazione in qualità di docente al congresso Update in Ematologia tenutosi a Genova il 29 ottobre e il 19 novembre Partecipazione alla fase finale del concorso Under 40 in Hematology tenutosi a Verona il novembre 2015 con la presentazione: MFC-MRD assessment may drive post induction consolidation in intermediate risk AML. Is it time for MRD-Driven decision making?. Partecipazione in qualità di docente al congresso Next in CML tenutosi a Napoli il 16 maggio e a Bologna il 23 maggio 2016 Partecipazione in qualità di docente all Advisory Board sulla gestione delle asparaginasi nel trattamento delle LAL pediatriche e degli adulti tenutosi a Torino il 7 settembre Unione europea, Pagina 5 / 8

6 Presentazione al 22 EHA congress tenutosi a Madrid (E) dei posters Induction with tyrosine kinase inhibitors, consolidation with fludarabine, ara-c and daunoxome followed by allogeneic stem cell transplant is an effective and feasible strategy for Ph+ ALL patients, Optimization of minimal residual disease evaluation in acute myeloid leukemia to drive post remission therapy., MRD-driven choice of consolidation and modulation of induction and consolidation intensity resulted in a significantly improved outcome of younger AML patients in the last three years, Treatment of molecular relapse in acute myeloid leukemia with mutated NPM1 reduces toxicity of salvage treatment and improves disease clearance., Cytogenetic and molecular risk factors at diagnosis are overcome by WT1 and flow cytometry-based pre transplant minimal residual disease assessment in advanced acute myeloid leukemia patients., A comprehensive analysis of patient- and therapy-related factors affecting the toxicity of pegylated-asparaginase for the treatment of adult acute lymphoblastic leukemia., and Retrospective evaluation on efficacy and feasibility of R-CODOX-M/IVAC regimen in aggressive DLBCL. Comunicazione Orale al 46 Congresso della società Italiana di Ematologia, tenutosi a Roma (I) in Ottobre 2017 del lavoro: Minimal residual disease assessment in Acute Myeloid Leukemia with mutated NPM1: prospective evaluation and MRD directed therapy, partecipazione della stesura del lavoro presentato oralmente allo stesso congresso: The choice of cut off value at different time points is crucial to improve the prognostic role of minimal residual disease evaluation in acute myeloid leukemia. Presentazione del poster Comprehensive analysis of patient- and therapy-related factors affecting the toxicity of pegylated-asparaginase for the treatment of adult acute lymphoblastic leukemia Presentazione al 59th ASH annual meeting and exposition tenutosi in Dicembre 2017 ad Atlanta (GA): First Report of the Gimema LAL1811 Phase II Prospective Study of the Combination of Steroids with Ponatinib As Frontline Therapy of Elderly or Unfit Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia, Glutamine-Dependence Targeting By Asparaginase Significantly Increases Anti-Myeloma Activity of Proteasome Inhibitors, Comparison of the Efficacy and Feasibility of R-CODOX-M/IVAC-R Versus Conventional R-CHOP As First Line Regimen for High Risk Diffuse Large B-Cell Lymphoma, Pre-Transplant Minimal Residual Disease Evaluation Performed By Molecular WT1-Based or Multicolor Flow Cytometry Assessment Overcomes the Prognostic Value of Cytogenetic and Molecular Risk Factors at Diagnosis in Advanced Acute Myeloid Leukemia Patients, Patient and Therapy-Related Factors Affecting the Toxicity of Pegylated-Asparaginase for the Treatment of Adult Acute Lymphoblastic Leukemia. Conferenze Partecipazione in qualità di docente al congresso internazionale Management of invasive fungal infections in neutropenic patients: overview on prophylaxis and therapy tenutosi il 5/03/2013 a Genova (NH Marina). Partecipazione alla fase finale del concorso Under 40 in Hematology tenutosi a Torino il novembre 2013 con il progetto di ricerca: CGH/SNP Array and Next Generation Sequencing in newly diagnosed AML a possible role in risk stratification and prognostic evaluation. Partecipazione alla fase finale del concorso Under 40 in Hematology tenutosi a Roma il novembre 2014 con la presentazione: Total Lymphoid Irradiation with helical tomotherapy (tomo-tli) followed by High-Dose Melphalan and Autologous Hematopoietic Stem-Cell Transplantation (ahsct) for Relapsed and Refractory Hodgkin Lymphoma. Partecipazione in qualità di docente al congresso Update in Ematologia tenutosi a Genova il 29 ottobre e il 19 novembre Partecipazione alla fase finale del concorso Under 40 in Hematology tenutosi a Verona il novembre 2015 con la presentazione: MFC-MRD assessment may drive post induction consolidation in intermediate risk AML. Is it time for MRD-Driven decision making?. Partecipazione in qualità di docente al congresso Next in CML tenutosi a Napoli il 16 maggio e a Bologna il 23 maggio 2016 Partecipazione in qualità di docente all Advisory Board sulla gestione delle asparaginasi nel trattamento delle LAL pediatriche e degli adulti tenutosi a Torino il 7 settembre Unione europea, Pagina 6 / 8

7 Partecipazione come Speaker Invitato al Congresso nazionale del Gruppo Italiano di Trapianto di Midollo Osseo, tenutosi a Milano a Maggio Partecipazione alla fase finale del concorso Under 40 in Hematology tenutosi a Lazise (VR) il novembre 2017 con il progetto di ricerca: Pre-Transplant Minimal Residual Disease Evaluation Performed By Molecular WT1-Based or Multicolor Flow Cytometry Assessment Overcomes the Prognostic Value of Cytogenetic and Molecular Risk Factors at Diagnosis in Advanced Acute Myeloid Leukemia Patients. Altro Reviewer dal 2015 per PLOSone Consulente per le Leucemie Acute Mieloidi e Leucemie Acute Linfoidi per Jazz Pharma Premi ed Onorificenze Società Scientifiche Travel grant winner al congress EHA 2015 in Vienna (A) e al congresso EHA 2016 in Copenaghen (DK) Vincitore di Abstract achievement award al congress ASH 2015 in Orlando (F) e al congresso ASH 2016 in S. Diego (CA) Vincitore del Abstract award sponsorizzato dalla Bigi Association nel 2016 a S. Diego (CA) Membro della società Europea di Ematologia ( European Hematology Association, EHA) Membro della società Europea di Trapinato di Midollo Osseo ( European Bone Marrow Transplantation association, EBMT) Membro della società Italiana di Ematologia (SIE) Unione europea, Pagina 7 / 8

8 Dichiaro che le informazioni riportate nel presente Curriculum Vitae sono esatte e veritiere. Autorizzo il trattamento dei dati personali, ivi compresi quelli sensibili, ai sensi del D.Lgs n Codice della Privacy - e successive modifiche e integrazioni. Genova, 11 Giugno 2018 Unione europea, Pagina 8 / 8